Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy

Publication | Open Access

DOI Full Paper Access

Citations

References

2017

Year

Michael Friedländer, Jörn Rau, Chee Khoon Lee, Werner Meier, Anne Lesoin, Jae‐Weon Kim, Andrés Poveda, Martin Buck, Giovanni Scambia, Muneaki Shimada,

Annals of Oncology

Abstract

References